Text Size

Epidemiology of Impaired Coagulant Balance in Diabetes

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00005481
First received: May 25, 2000
Last updated: June 23, 2005
Last verified: July 2004
History of Changes
  Purpose

To determine the nature, extent and molecular mechanisms responsible for impaired fibrinolysis in White, Black, Hispanic and American Indian populations with respect to the presence or absence of diabetes. The overall objective is to determine whether impairments of fibrinolysis underlie subclinical and clinical vascular disease in diabetes in specific populations with and without accelerated microvascular disease.


Condition
Cardiovascular Diseases
Heart Diseases
Diabetes Mellitus
Blood Coagulation Disorders

Study Type: Observational
Study Design: Observational Model: Natural History

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 1996
Estimated Study Completion Date: July 2002
Detailed Description:

BACKGROUND:

The results of this project should clarify the extent to which results obtained in experimental animals pertain directly to diabetes in human subjects. The study will also assist in the interpretation of results from clinical studies and from platelet activation experiments.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

No eligibility criteria

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005481

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Investigator: Russell Tracy University of Vermont
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00005481     History of Changes
Other Study ID Numbers: 4965
Study First Received: May 25, 2000
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Blood Coagulation Disorders
Hemostatic Disorders
Cardiovascular Diseases
Diabetes Mellitus
Heart Diseases
Hematologic Diseases
 Vascular Diseases
Hemorrhagic Disorders
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 16, 2013